News in brief - September 2014 (updated)

Other new launches, licence changes and updates relevant to general practice.

In clinical studies, telavancin showed non-inferiority to vancomycin in the treatment of hospital-acquired pneumonia.
In clinical studies, telavancin showed non-inferiority to vancomycin in the treatment of hospital-acquired pneumonia.
  • From 1st September, Zostavax should be offered to individuals aged 70 years for the routine shingles immunisation programme and those aged 78 or 79 years for the catch-up programme. 
  • The antiemetic domperidone (Motilium) will now be available only as a POM.
  • Malaria prevention advice for India and Sri Lanka has changed; prophylaxis is now recommended only for travel to the states of Assam and Orissa and certain districts of Andhra Pradesh and Madhya Pradesh in India and is no longer recommended for any area of Sri Lanka.
  • Clinigen has launched a new glycopeptide antibacterial, telavancin (Vibativ), for treating nosocomial pneumonia known or suspected to be caused by MRSA.
  • Stivarga (regorafenib) is now licensed for the treatment of unresectable or metastatic gastrointestinal stromal tumour that has progressed on imatinib and sunitinib, or where these agents are not tolerated.

Follow MIMS on Twitter

Sign up for MIMS bulletins

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in